Chiesi has held an inauguration ceremony for an expanded manufacturing facility in La Chaussée-Saint-Victor, France where the company will manufacture metered dose inhalers with low global warming potential (LGWP) propellants, the company said. Earlier this year, Chiesi announced plans for an LGWP MDI manufacturing facility in Nerviano, Italy.
The company says that the newly expanded French facility is expected to employ 300 people by 2026, adding approximately 50 new jobs. According to Chiesi’s web site, the La Chaussée-Saint-Victor facility manufactures both MDIs and DPIs, with a a capacity of 25 million MDI packages and 9 million DPI packages annually.
In December 2019, Chiesi announced that it planned to bring an HFA 152a inhaler to market by the end of 2025. In September 2025, Chiesi said that it had completed a Phase 3 trial of its CHF5993 beclometasone / formoterol / glycopyrronium MDI formulated with HFA 152a, and in October, the company said that the FDA had accepted an NDA for the MDI.
Chiesi Group Vice Chair Maria Paola Chiesi commented, “This inauguration represents much more than an industrial success. It illustrates our commitment to creating an environment where everyone contributes to a common goal: innovating for the well-being of the patients and the communities we serve, while safeguarding our planet. Every day, we act to have a positive impact on patients, communities, and the environment. This is integral to our vision of the company’s role within society.”
Maria Paola Chiesi added, “Europe has all the assets to succeed: scientific and manufacturing expertise, exceptional talent, and a long tradition of excellence in public health. Here, in La Chaussée-Saint-Victor, we demonstrate that Europe can not only participate in this global transformation towards sustainable development but also lead it. To achieve this, Europe must offer an environment worthy of its ambitions—one that attracts investments, accelerates transformation, and ensures equitable access to innovation for all.”
Read the Chiesi press release
